ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / PLSE
NVST (49) IRTC (48) ICUI (59) ATRC (63) ⌘ Pro Terminal β†’

Pulse Biosciences Inc (PLSE) β€” RQD Stock Rating Cockpit

$52.24 -5.84% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $51.59

Pulse Biosciences Inc (PLSE) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (41/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE D- β€’ RED ALERT Cap $3.96B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PLSE Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PLSE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Pulse Biosciences Inc (NASDAQ: PLSE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $52.24 (-5.84% 1D, market cap $3.96B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLSE ranks #492 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PLSE compare to NVST and IRTC in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), PLSE carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -30.7%. By comparison, NVST (Envista Holdings Corporation) holds a D grade (49/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.95B) and IRTC (iRhythm Holdings Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -13.5%, cap $4.21B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PLSE?
β–Ό

Per PLSE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625101), Pulse Biosciences Inc generated $350.0K in revenue, -$72.8M in net income, and -$54.4M in free cash flow against $94.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $51.59 (-1.24%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (41/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510041
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D-
Cash (6)Whales (16)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
$62 Bull$48 Base$38 Bear
πŸ“¬ FREE PLSE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PLSE)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (41/100 Composite)
πŸ” WHY PLSE SCORES 41/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+16/20 pts (39% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (20% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
49
Grade D$52.45-9.3% Next Q
Q2 (-2Q)
46
Grade D$47.55+10.7% Next Q
Q3 (-1Q)
44
Grade D$52.66-0.8% Next Q
Current
41
Grade D-$52.24-7.2% Hist 90D Ξ±
Trajectory: D (49) β†’ D- (41)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PLSE Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PLSE currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($51.18) and Max Pain ($54.85) forces dealer call-delta covering toward $61.84.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PLSEβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPLSE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 41%NO 59%Trade / Inspect Odds β†’
RSI-14 MOMENTUMBULLISH MOMENTUM
59.730 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE86% OF RANGE
L: $13$52.24H: $59
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on PLSE

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-30.7% ROIC with -30.0% gross margin and -1.38% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (45)

19/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like PLSE
  • βœ“Big institutional funds and options desks are actively positioning on the bullish side.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLSE)

  • βœ“Walkthrough of PLSE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PLSE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +160.81%β–² ASCENDING CHANNEL
2026-11-02O $53.67H $55.48L $52.24C $52.24VOL 344.7K
RES: $76.39SUP: $46.38SMA50: $51.18SMA200: $31.56
$61.82$49.73$37.64$25.55$13.46RES $76.39SUP $46.38$52.242026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PLSE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PLSE Butterfly Map β†’ + Track PLSE β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PLSE today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PLSE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PLSE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLSE)

Health Care Rank #492 of 1016 βš”οΈ NVST vs PLSE Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PLSE vs. NVST, IRTC, ICUI, ATRC)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Pulse Biosciences Inc (PLSE) ranks #492 by composite RQD confidence (41/100, grade D-) and #184 by equity capitalization ($3.96B). Within this direct 5-issuer industry benchmark cohort, NVST leads on earnings valuation at 84.1x trailing P/E, while NVST leads on capital efficiency and profitability with 5.1% ROIC and 54.7% gross margin. ATRC currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with PLSE at 41/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PLSE ACTIVE
Pulse Biosciences Inc
D- 41/100 β€” -30.0% -30.7% -5.84% $3.96B Benchmark Subject
NVST
Envista Holdings Corporation
D 49/100 84.1x 54.7% 5.1% -4.47% $3.95B /nvst-vs-plse β†’
IRTC
iRhythm Holdings Inc.
D 48/100 β€” 70.6% -13.5% -3.47% $4.21B /irtc-vs-plse β†’
ICUI
ICU Medical Inc.
C- 59/100 β€” 36.8% 1.0% -2.89% $4.22B /icui-vs-plse β†’
ATRC
AtriCure Inc.
C 63/100 β€” 75.0% -1.9% -1.97% $3.18B /atrc-vs-plse β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001625101

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Pulse Biosciences Inc (PLSE) reported GAAP revenue of $350.0K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$72.8M, operating cash flow of -$54.1M, and free cash flow of -$54.4M (-49.3% YoY). On the balance sheet, PLSE closed FY2025 with $94.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $350.0K -$72.8M -$54.1M -$54.4M $94.5M β€”
FY2024 (FY) 2024-12-31 $0 -$53.6M -$36.3M -$36.5M $132.5M β€”
FY2023 (FY) 2023-12-31 $0 -$42.2M -$33.0M -$33.0M β€” β€”

3. PLSE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PLSE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Pulse Biosciences Inc (NASDAQ: PLSE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $52.24 (-5.84% 1D, market cap $3.96B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLSE ranks #492 in composite RQD confidence.

How does PLSE compare to NVST and IRTC in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PLSE carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -30.7%. By comparison, NVST (Envista Holdings Corporation) holds a D grade (49/100 RQD, P/E 84.1x, ROIC 5.1%, cap $3.95B) and IRTC (iRhythm Holdings Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC -13.5%, cap $4.21B). Among the 5-stock peer group, NVST leads on earnings multiple (84.1x) while NVST leads on capital efficiency (5.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PLSE?

Per PLSE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625101), Pulse Biosciences Inc generated $350.0K in revenue, -$72.8M in net income, and -$54.4M in free cash flow against $94.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PLSE trading relative to its 50-day, 200-day, and 52-week technical levels?

PLSE last traded at $52.24 (-5.84% on volume of 466,482 shares), positioning the stock +2.07% above its 50-day simple moving average ($51.18) and +65.53% above its 200-day simple moving average ($31.56). Across its 52-week range of $12.56 to $58.90, PLSE sits at the 85.6% percentile with a 14-day RSI of 59.7 (BULLISH MOMENTUM) and an implied next-earnings move of Β±12.5% ($45.71 to $58.77).

PLSE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell PLSE stock right now?

Pulse Biosciences Inc (PLSE) currently earns a Roarable Rating of D- (Sell β€” SELL) with 41/100 RQD Confidence. Stretched risk/reward at current multiples (-31% return on capital) under elevated 10-year interest-rate pressure.

What is PLSE's 12-month price target and RQD AI Jury consensus?

PLSE's 12-month base price target is $48.24 (range $37.63 to $61.84), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PLSE RQD Cockpit PLSE 12M Forecast PLSE Earnings & Move PLSE Dividends & DRIP PLSE Insiders & 13F PLSE Whale Options PLSE Profit Sankey PLSE News & Why
ROARABLE RATING BRIEF β€’ RQD 41/100 (D-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

PLSE β€” Pulse Biosciences Inc: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:22:36Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD Score is 41 / D-, labeled "Roarable Sell β€” Vulnerable Balance Sheet & Flow," per the Roarable RQD rating. Across its five pillars:

  • Fundamental Cash Engine (6 / 20): Per the Roarable RQD rating, ROIC is -30.7% and FCF yield is -1.38%. This is the weakest-scoring pillar and indicates the business is not currently generating cash returns on invested capital. For a prospective investor, the valuation case rests on future cash generation that the reported history does not yet show.
  • Whale / 13F Flow (16 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar, suggesting institutional interest is a meaningful support factor, though the source data does not itemize the 13F holdings.
  • Insider Conviction (3 / 20): Per the Roarable RQD rating, this reflects SEC Form 4 and Congressional PTR cluster flow. The low score signals weak insider-side confirmation of the thesis.
  • Macro Regime Fit (8 / 20): Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The stock moves in line with the market, offering no defensive cushion.
  • Forensic Balance Sheet (8 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These are mixed-to-weak readings that point to limited financial resilience.

Investor implication: the upside case depends on the stock's momentum and institutional support outrunning weak cash generation and a modest balance sheet. Valuation tradeoffs are significant because standard earnings multiples are not available in the source data. This analysis is educational and not personalized financial advice.

Business

Pulse Biosciences Inc (PLSE) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry, per the company profile. The source data does not describe its specific products, customers, or revenue model beyond reported revenue of $0.3M for FY 2025 per the SEC financials. Its sector and industry classification places it within medical instrument manufacturing.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.3M$-76.9M$-72.8MN/A$-54.4M$80.7MN/A
FY 2024$0.0M$-56.3M$-53.6MN/A$-36.5M$118.0MN/A
FY 2023$0.0M$-43.6M$-42.2MN/A$-33.0MN/AN/A

Per the SEC financials, the company has reported losses in each period, with operating losses widening from $-43.6M (FY 2023) to $-76.9M (FY 2025). Per the market data, gross margin is -30%, operating margin is -60%, and net margin is -60%. ROIC is -30.7%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Cash declined from $118.0M (FY 2024) to $80.7M (FY 2025), and debt is reported as N/A in the source data.

Recent Catalysts & News Wire Analysis

  • Canaccord price target raise: Per the news wire, Canaccord raised its price target on the tech potential, categorized as a green-light item tagged CATALYST.
  • Fair value / analyst target increases: Per the news wire, a Yahoo Finance report covers fair value rising after analyst target increases (yellow, MARKET WIRE).
  • Clayman partnership: Per the news wire, a Simply Wall St piece asks whether the stock is fully priced as the Clayman partnership builds commercial and clinical traction (green, CATALYST).
  • Inducement grants: Per the news wire, Business Wire reports inducement grants under Nasdaq Listing Rule 5635(c)(4) (yellow, MARKET WIRE).
  • Watch item: Several items are general market-wire coverage without specific fundamental detail.

Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals.

Open Questions

  • What are the company's specific products, customers, and revenue drivers, given that FY 2025 revenue is only $0.3M?
  • What is the total debt position, since debt is reported as N/A across all periods?
  • What is the path to positive free cash flow, given FCF of $-54.4M in FY 2025?
  • What are the terms and milestones of the Clayman partnership referenced in the news wire?
  • What is the institutional and 13F holder breakdown behind the 16 / 20 whale-flow pillar?

PLSE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Pulse Biosciences Inc (PLSE) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PLSE Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PLSE Bull vs. Bear Conversation Board β€” What's Your Call at $52.24?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PLSE 🐻 67% BEARISH CONVICTION
1. Pick Your Side on PLSE:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $48.82 (-12.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is PLSE (D- β€’ RQD 41/100) a Buy at $55.48?

Welcome to the PLSE (Pulse Biosciences Inc) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell β€” Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $42.16 (-24.0%)
Spot @ $55.48

Pump the brakes on PLSE β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PLSE, but look at what you are paying: current EV/EBITDA multiples with -30.0% gross margins. Unless Pulse Biosciences Inc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $67.69 (+22.0%)
Spot @ $55.48

PLSE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PLSE, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $55.48 (52-wk range $12.56 - $58.90), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%